Chest: The detection of PD-L1 expression in specimens obtained by bronchial ultrasound-guided needle aspiration (EBUS-TBNA) can also guide the application of PD1 inhibitors in patients with advanced NSCLC

Studies on advanced lung cancer have shown that the detection of PD-L1 is feasible in specimens obtained by bronchial ultrasound-guided needle aspiration (EBUS-TBNA) .
However , it is still unclear whether the detection of PD-L1 expression in EBUS specimens and traditional tissue specimens is used to guide the efficacy of PD-1 inhibitor therapy .
Therefore, a team from Canada has carried out related studies to evaluate whether the detection of PD-L1 expression in EBUS specimens and traditional tissue specimens can guide the efficacy of PD-1 inhibitors in the treatment of patients with advanced NSCLC .
Related research results were published in Chest magazine .

Studies on advanced lung cancer have shown that the detection of PD-L1 is feasible in specimens obtained by bronchial ultrasound-guided needle aspiration (EBUS-TBNA) .

However , it is still unclear whether the detection of PD-L1 expression in EBUS specimens and traditional tissue specimens is used to guide the efficacy of PD-1 inhibitor therapy .
Therefore, a team from Canada has carried out related studies to evaluate whether the detection of PD-L1 expression in EBUS specimens and traditional tissue specimens can guide the efficacy of PD-1 inhibitors in the treatment of patients with advanced NSCLC .
Related research results were published in Chest magazine .
Lung cancer bronchial ultrasound-guided needle aspiration (EBUS-TBNA) specimens are feasible

Patients who received pembrolizumab or nivolumab between June 2016 and June 2019 were included in the study
.

Collect patient characteristics, PD-L1 expression, number of treatment lines, and efficacy

Patients who received pembrolizumab or nivolumab between June 2016 and June 2019 were included in the study

A total of 145 patients were enrolled, including 46 EBUS-TBNA (31.

At a median follow-up of 11 months, 90 patients died, including 29 (63%) EBUS-TBNA and 61 (61.

The prognostic difference of the first-line pembrolizumab treatment between the two groups

The prognostic difference of the first-line pembrolizumab treatment between the two groups

In patients who received pembrolizumab or nivolumab in the posterior line, the median PFS (HR=0.
89, 95%CI, 0.
54-1.
46) and OS (HR=0.
98, 95%CI, 0.
58-1.
64) were not statistically different between the two groups
.

In patients who received pembrolizumab or nivolumab in the posterior line, the median PFS (HR=0.
89, 95%CI, 0.
54-1.
46) and OS (HR=0.
98, 95%CI, 0.
58-1.
64) were not statistically different between the two groups
.

In patients who received pembrolizumab or nivolumab in the posterior line, the median PFS (HR=0.

            The prognosis difference between the two groups after ICI treatment

The prognosis difference between the two groups after ICI treatment

A subgroup analysis of age, gender, stage, PD-L1 expression level, pathological tissue type (squamous cell carcinoma vs non-squamous cell carcinoma), CNS metastasis status or smoking status found that there was also no statistical difference in PFS and OS between the two groups
.

A subgroup analysis of age, gender, stage, PD-L1 expression level, pathological tissue type (squamous cell carcinoma vs non-squamous cell carcinoma), CNS metastasis status or smoking status found that there was also no statistical difference in PFS and OS between the two groups
.

                Prognostic differences in subgroup analysis

Prognostic differences in subgroup analysis

In summary, studies have shown that there is no significant difference between EBUS specimens and traditional tissue specimens to detect PD-L1 expression in guiding the efficacy of PD-1 inhibitors in the treatment of patients with advanced NSCLC
.

In summary, studies have shown that there is no significant difference between EBUS specimens and traditional tissue specimens to detect PD-L1 expression in guiding the efficacy of PD-1 inhibitors in the treatment of patients with advanced NSCLC
.

Studies have shown that EBUS specimens and traditional tissue specimens to detect PD-L1 expression have no significant difference in guiding the efficacy of PD-1 inhibitors in the treatment of patients with advanced NSCLC

Original source:

Tajarernmuang P, Ofiara L, Beaudoin S, Wang H, Benedetti A, Gonzalez AV.

Tajarernmuang P, Ofiara L, Beaudoin S, Wang H, Benedetti A, Gonzalez AV.
Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
Chest.
2021 Aug;160(2):743-753.
doi: 10.
1016/j.
chest.
2021.
02.
053.
Epub 2021 Mar 3.
PMID: 33675792.
Leave a message here